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ABSTRACT
Testing for HER2/neu in breast cancer at the time of
primary diagnosis is now the standard of care. Accu-
rate and standardized testing methods are of prime
importance to ensure the proper classification of the
patient’s HER2/neu status. A meeting of pathologists
from across Canada was convened to update the Ca-
nadian HER2/neu testing guidelines. This National
HER2/neu Testing Committee reviewed the recently
published American Society of Clinical Oncology/
College of American Pathologists (ASCO/CAP) guide-
lines for HER2/neu testing in breast cancer. The up-
dated Canadian HER2/neu testing guidelines are based
primarily on the ASCO/CAP guidelines, with some modi-
fications. It is anticipated that widespread adoption
of these guidelines will further improve the accuracy
of HER2/neu testing in Canada.
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1. INTRODUCTION
The human epidermal growth factor 2 (HER2/neu)
gene is amplified in approximately 18%–20% of
breast cancers 1–4, and it is the primary mechanism
for  HER2 protein overexpression 5. Overexpression of
HER2 is predictive of response to particular therapies,
including trastuzumab (Herceptin: Genentech, San
Francisco, California, U.S.A.) treatment in the meta-
static and adjuvant settings 1,6–10.
Recognizing the importance of accurate HER2/neu
status assessment, pathologists from across Canada
gathered to share local testing experiences and in-
sights. The meeting was chaired by Dr. Wedad Hanna
and Dr. Frances P. O’Malley, who facilitated the col-
laboration to create a Canadian consensus statement
for HER2 testing procedures.
The American Society of Clinical Oncology
(ASCO) and the College of American Pathologists (CAP)
convened an expert panel to develop a U.S. guide-
line to improve the accuracy of HER2 testing in inva-
sive breast cancer. This ASCO/CAP guideline was
reviewed by the panel of Canadian pathologists. The
data from that review and the experience of the panel
members were used to create the current update of
the Canadian HER2 testing guidelines and algorithm
(Figure 1). The updated information is presented here.
2. CONSENSUS PARTICIPANTS
Co-chairs: Wedad Hanna MD (Toronto, Ontario) and
Frances P. O’Malley  MD (Toronto, Ontario)
Delegates: Penelope Barnes MD (Halifax, Nova
Scotia), Richard Berendt MD (Edmonton, Alberta),
Louis Gaboury MD (Montreal, Quebec), Anthony
Magliocco MD (Calgary, Alberta), Norman Pettigrew
MD (Winnipeg, Manitoba), Susan Robertson MD
(Ottawa, Ontario), Sandip Sengupta MD (Kingston, On-
tario), Bernard Têtu MD (Québec City, Quebec), and
Thomas Thomson MD (Vancouver, British Columbia)
The information that follows is based both on the
experience of the consensus participants and on the
recently published ASCO/CAP Guideline Recommen-
dations for HER2/neu Testing in Breast Cancer.
3. ISSUES CONSIDERED BY THE
CONSENSUS PARTICIPANTS
3.1 Testing at Diagnosis
The HER2/neu gene has proved to be a significant
prognostic and predictive biologic marker in breast
cancer 1. Thus, the current standard of care is to test
all patients with invasive breast cancer for HER2/neu
at the time of diagnosis 1.
The panel agreed that standardized and validated
tests should be performed. Available data do not show
superiority for either immunohistochemistry (IHC) or
in situ hybridization (ISH) as a predictor of benefit
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from Herceptin therapy. The testing algorithm pro-
posed for all invasive breast cancers is based on the
very high concordance between HER2/neu gene am-
plification and protein expression as determined using
accurate and reproducible assay methods. Thus, the
Canadian consensus agrees with the ASCO/CAP guide-
lines and is based on testing first with IHC and then
retesting equivocal cases using ISH [either fluorescent
(FISH) or another validated brightfield ISH method such
as chromogenic (CISH) or silver-enhanced (SISH)] 1.
Throughout the current document, the use of FISH
methodology is not exclusive; labs can use other vali-
dated ISH methods to assess equivocal cases both for
clinical case and quality assurance (QA) activities.
The guidelines and variables related to accurate
testing are discussed under the headings pre-analytic,
analytic, and post-analytic.
3.2 Pre-analytic
3.2.1 Tissue Handling and Fixation
Time from specimen excision to placement in fixa-
tive should be minimized. Samples should be sliced
immediately at 5–10 mm intervals after appropriate
gross inspection and designation of margins and then
placed in a sufficient volume of 10% neutral buffered
formalin 1. Optimal time of fixation is 24–48 hours in
10% neutral buffered formalin, but a period of at least
6 hours 11 is sufficient for core biopsy specimens. A
fixation time longer than 48 hours for lumpectomy/
mastectomy specimens is not an exclusion criterion
for HER2 testing (Table I) provided that the specimen
has been appropriately sectioned to allow adequate
fixation as described above. Under-fixation is more
critical than over-fixation; less than 6 hours’ fixation
time precludes the specimen from being used for HER2
testing. The fixation requirements described above
pertain to testing both with IHC and with FISH.
3.3 Analytic
3.3.1 Assay validation
When validating a new antibody, 25–100 samples
should be tested 1. However, if the lab has little expe-
rience with performing HER2 testing, a minimum of
100 sample tests is advisable. An assay accuracy of
95% concordance rate should be achieved for both the
positive and negative categories. Adequate validation
should be ensured, preferably by using 50% cases that
are unequivocally positive and 50% cases that are un-
equivocally negative. Validation documentation must
be kept. Any modification to the procedure requires
additional validation to ensure accurate performance.
3.3.2 Type of Antigen Retrieval
Stringent compliance to validated standard operat-
ing procedures developed in assay validation must
be adhered to and quality control (QC) documenta-
tion must be in place.
3.3.3 Use of Standard Control Materials
The controls should include positive (overexpressed/
amplified) and negative (not overexpressed/not am-
plified) cases, plus a low amplified/low protein over-
expression case if possible. The control tissue should
be fixed and processed in the same manner as the
patient samples.
3.3.4 Use of Automated Lab Methods
The use of correctly operated automated staining pro-
tocols and equipment are acceptable, but validated
methods must be used. Maintenance and service records
should be regularly updated and filed in the laboratory.
3.4 Post-analytic
3.4.1 Image Analysis
Use of image analysis systems can be useful to en-
hance reproducibility of scoring; pathologists must
supervise all image analyses.
3.4.2 Mandatory reporting elements, IHC
The panel agreed that mandatory reporting elements
for IHC testing include these items 1:
• Patient identification information
• Physician identification
• Date of service
• Specimen identification (case and block number)
• Specimen site and type
• Specimen fixative type (if not 10% neutral buff-
ered formalin)
• Time to fixation (if available)
• Duration of fixation (if available)
• Antibody clone and vendor
• Method used (test and vendor)
• Image analysis method (if used)
• Adequate controls
• Adequacy of sample for evaluation
• Results:
• Percentage of invasive tumour cells exhibit-
ing complete membrane staining
• Uniformity of staining: present or absent
• Homogenous, dark circumferential pattern:
present or absent
• Interpretation (Table II):
• Positive (for HER2 protein expression)
• Equivocal (FISH will be done and reported)
• Negative (for HER2 protein expression)
• Not interpretable
3.4.3 Mandatory reporting elements, FISH
The panel agreed that mandatory reporting elements
for FISH testing include these items 1:
• Patient identification information
• Physician identification
• Date of service
• Specimen identification (case and block number)HANNA et al.
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• Specimen site and type
• Specimen fixative type (if not 10% neutral buff-
ered formalin)
• Time to fixation (if available)
• Duration of fixation (if available)
• Identification of probe (or probes)
• Method used (specifics of test and vendor)
• Image analysis method
• Adequate controls
• Adequacy of sample for evaluation (adequate
number of invasive tumour cells present)
• Results:
• Number of invasive tumour cells counted
• Number of observers (optional)
• Average number of HER2 signals per nucleus
or tile a
• Average number of chromosome enumera-
tion probe 17 (CEP 17) signals per nucleus or
tile a
• Ratio of average HER2 signals to CEP 17
signals
• Interpretation (Table III):
• Positive (amplified)
• Equivocal
• Negative (not amplified)
• Not interpretable
• If IHC is being done because of problems with
assay or results, that fact should also be
included
3.4.4 Volume
Per the United Kingdom guidelines, each lab should
perform at least 250 IHC tests 12. If the lab also per-
forms FISH, then at least 100 FISH tests should be per-
formed annually. However, given the complexity of
the procedure and the experience needed, it is advis-
able and preferable to perform at least 200 FISH tests
annually.
Appropriate training for pathologists should take
place, and the number of tests performed by each
pathologist should be considered to ensure compe-
tency. Test volume should be assessed in conjunc-
tion with the lab’s adherence to strict QC and QA
practices. Technologists should undergo appropriate
training, including ongoing education in FISH tech-
nology and interpretation.
3.5 QA Procedures
3.5.1 Optimal Internal QA Procedures
The panel recommends that initial test validation
should take place together with ongoing QC and equip-
ment maintenance. Initial and ongoing education of
laboratory personnel, training, and competency as-
sessment should also be implemented. The use of
standardized operating procedures, including routine
use of control materials, should be enforced, and
modified procedures should be revalidated. Finally,
ongoing competency assessment and education of
pathologists should take place.
3.5.2 Optimal External Proficiency Assessment
The panel agreed that participation in an external pro-
ficiency testing program with at least two testing
events (mailings) annually is mandatory. Also, satis-
factory performance requires at least 90% correct
responses in graded challenges for either test. Unsat-
isfactory performance will require a laboratory to
respond according to accreditation agency program
requirements.
3.5.2 Optimal Laboratory Accreditation
Onsite inspection should take place every other year
with an annual requirement for self-inspection. Re-
view of laboratory validation, procedures, QA results
and processes, results, and reports should be put into
place. Unsatisfactory performance results in suspen-
sion of laboratory testing for HER2 for that method.
3.5.3 Statistical Requirements for Assay Validation
“Sensitivity” is defined as the percentage of positive
test results obtained when evaluating only specimens
that are truly positive. “Specificity” is defined as the
percentage of negative test results reported when only
truly negative specimens are evaluated. “Overall ac-
curacy” (concordance) combines sensitivity and
specificity into a single measure of the percentage of
cases (positive and negative) for which the assay re-
sult agrees with the true status. Note that overall ac-
curacy (concordance rate) can be strongly influenced
by the positive–negative mix of the test case set if
the sensitivity and specificity rates are not similar.
Examples of external QA programs include these:
• CAP (www.cap.org)
• U.K. National External Quality Assessment Ser-
vice (NEQAS: www.ukneqas.org.uk)
• Nordic Immunohistochemical Quality Control
(NordiQC: www.nordiqc.org)
• Ontario [overseen by Quality Management Pro-
gram–Laboratory Services (www.qmpls.org) and
Cancer Care Ontario (www.cancercare.on.ca)]
3.5.4 Algorithm for IHC and FISH
The panel agreed that pathologists should test at diag-
nosis, starting with IHC and then, in equivocal cases,
moving to FISH or to another validated brightfield
in situ hybridization method such as CISH or SISH. In
cases in which the available sample is small or the
sample is a core biopsy in the neoadjuvant setting, it
is preferable to perform ISH as the initial test (Figure 1).
4. CONCLUSIONS
Considering the prognostic and predictive signifi-
cance of determining HER2/neu status in invasive a “Tile” is the unit used for image-system counting.PRACTICE GUIDELINE SERIES
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breast cancer, HER2/neu testing performed at the time
of initial diagnosis is now the standard of care. In
line with the updated ASCO/CAP guidelines, the Cana-
dian consensus guidelines provide recommendations
on how to evaluate and report HER2/neu over-
expression and gene amplification. In summary, the
guidelines outline specific criteria that laboratories
must meet before engaging in HER2/neu testing.
The 2007 HER2/neu testing algorithm integrates
both the IHC and the FISH algorithms as published in
the ASCO/CAP guidelines. It is important to note that
the cut-offs for positivity for both IHC and FISH have
been updated; a positive IHC result is now defined as
>30% strong complete membrane staining; a positive
FISH result is defined as a ratio > 2.2 or a HER2 gene
copy > 6.0.
With continual efforts being made to optimize
HER2/neu testing accuracy, the testing guidelines and
algorithm will be regularly updated to convey cur-
rent practices.
TABLE III Interpretation criteria, fluorescence in situ hybridization
(FISH)
Result category FISH score (HER2 gene amplification)
Positive HER2:CEP 17 ratio > 2.2
or
Average HER2 gene copy number > 6 a
Equivocal HER2:CEP 17 ratio = 1.8–2.2 b,c
or
Average HER2 gene copy number = 4–6 a
Negative HER2:CEP 17 ratio < 1.8
or
Average HER2 gene copy number < 4 a
a Signals or nucleus for test systems without an internal chromo-
some 17 centromeric probe.
b Count additional cells, or test another block for immunohis-
tochemistry (IHC) and FISH if necessary.
c Patients with a HER2 gene amplification of ³2 were eligible for
adjuvant trastuzumab trials.
CEP 17 = chromosome enumeration probe 17.
TABLE II Interpretation criteria, immunohistochemistry (IHC)
Result IHC score Interpretation criteria
category (HER2 protein
expression)
Positive 3+ Strong, complete, homogeneous
membrane staining (chicken-wire
pattern) in >30% of cells
Equivocal a 2+ Strong, complete membrane staining
(chicken-wire pattern) in £30% of cells
Weak or moderate heterogeneous
complete membrane staining in at least
10% of cells
Negative 0–1+ No staining (0), or weak, incomplete
membrane staining (1+) in any
percentage of cells
a Confirm by fluorescence in situ hybridization (FISH) analysis of
original sample.
TABLE I Exclusion criteria, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)
Sample exclusion criteria to perform or interpret a HER2 IHC assay Sample exclusion criteria to perform or interpret a HER2 FISH assay
Tissue fixed using other than 10% neutral buffered formalin a Samples with only limited invasive cancer difficult to define under
Excisional and needle biopsies fixed for less than 6 hours ultraviolet light
Core needle biopsies with Tissue fixed in fixatives other than 10% neutral buffered formalin a
• edge or retraction artifact involving entire core Excisional or core biopsies fixed in formalin for less than 6 hours
• crush artifact (thin-gauge vacuum-extraction needle samples) Controls with unexpected results
Tissues with strong membrane staining of internal normal ducts or FISH signals non-uniform (<75% identifiable)
lobules Background obscures signal (>10% of signals over cytoplasm)
Tissues where controls exhibit unexpected results Non-optimal enzymatic digestion (poor nucleus resolution,
persistent autofluorescence)
a If a laboratory uses fixatives other than buffered formalin, it must validate the performance characteristics of the assay to show that those
characteristics are concordant with results using buffered formalin in the same samples.
FIGURE 1 Algorithm for immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH). Based partly on Wolff et al.1
† Evaluation of equivocal IHC results includes retesting with FISH or
other validation brightfield in situ hybridization techniques
[chromogenic in situ hybridization (CISH) or silver-enhanced in situ
hybridization (SISH)].HANNA et al.
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